European Journal of Surgical Oncology’s Post

Great news for patients and radiation oncologists! 77427 - our weekly management code will be allowed to be performed via telehealth. In addition, direct virtual supervision will continue until the end of 12/31/25. Free standing takes a hit (as it is the red-headed step child of radiation oncology; no offense to my scarlet coiffed colleagues) and hospitals get a boost. In other news, water is wet. Despite American Society for Radiation Oncology (ASTRO) best efforts to force 77427 to be in-person and to make sure linacs are baby-sat (direct supervision instead of general), the government agreed that there is no evidence to justify this over reach and slapped it down. Our society needs to listen more to its members, review evidence and collaborate with community radiation oncologists before dictating how we practice medicine. It is not a good look for the majority of membership to be against what ASTRO supports. What is the point of paying dues if the organization does the opposite of what membership wants? I am hoping with leadership changes, new CEO Vivek S. Kavadi, MD, MBA, FASTRO) will make an effort to work more closely with us. Dr. Kavadi -The invitation to chat or to be a guest on our show (The Accelerators Podcast) remains. We would love to have you and see what you have in store for ASTRO.

We're happy to announce Hospital La Fe de Valencia, one of Spain's Top 10 hospitals and a Top 200 hospital worldwide, has joined OncoSwab's clinical trials. The research, led by Thoracic Surgeon Dr. Alilis Fontana, will ensure access to real-world patients with suspicious pulmonary nodules and will contribute valuable data to validate the accuracy of OncoSwab’s non-invasive lung cancer test. We are honored to collaborate with Hospital La Fe and Dr. Fontana in advancing early lung cancer detection. Together, we aim to improve diagnostic pathways and provide better outcomes for patients. Stay tuned as we continue to expand our clinical trial network across Europe and the US!

My picks for special oral abstract mentions for American Society of Clinical Oncology (ASCO) - Sharlene Gill MD, MPH, MBA, FRCP(C), FASCO OncoAlert OncologyEducation #ASCO #Cancer #ColorectalCancer #ESOPEC #OncoDaily #Oncology #PancreaticCancer

✨Exciting update! EORTC’s #STRASS2 clinical trial has reached 125 enrolled patients, marking 50% of the overall accrual! STRASS 2 is the first international trial exploring whether chemotherapy before surgery can improve outcomes and survival for sarcoma patients. 🙏 A heartfelt thank you to our incredible investigators, dedicated staff, and especially to the 125 patients whose commitment made this progress possible. Special thanks to our funding partners for their essential support in making this trial a reality: Anticancer Fund, EORTC Soft Tissue and Bone Sarcoma Group, EORTC Cancer Research Fund, CLIMBERS AGAINST CANCER TRADING LIMITED, Cancer Research UK (CRUK), Sarcoma UK, Novo Nordisk Foundation, European Commission (Horizon Europe funding program, project 101103843), Australian Government Department of Health and Aged Care, the Australia and New Zealand Sarcoma Association, Patiëntenplatform Sarcomen, ECOG-ACRIN Cancer Research Group, Japan Clinical Oncology Group, and Canadian Cancer Trials Group. For more information: https://lnkd.in/e__464gr Winan van Houdt, Alessandro Gronchi #CancerResearch #Sarcoma #ClinicalTrials #Oncology

IceCure Medical announces positive data from the largest multi-institutional study of its kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials" ❄️ Investigator initiated independent study included higher risk patients such as those with metastatic disease, large tumors, and comorbidities, as compared to IceCure's #ICE3 study which treated early-stage breast cancer patients ❄️ Recurrence-free rates were 94.7%, 87.8%, and 81.8%, at 1, 2, and 3 years, respectively ❄️ Study published in American Journal of Roentgenology was conducted at 7 U.S. institutions and led by Principal Investigators Dr. Karim Oueidat and Dr. Robert C. Ward, M.D., both of the Warren Alpert Medical School of Brown University Learn more in our new press release: https://lnkd.in/d-kBsi6f

The future of Thoracic Oncology is in great hands! - Rami Manochakian https://lnkd.in/gFWRdhv3 #oncodaily #oncology #cancer #research #EarlyCareer #Physicians #Researchers

The Breast Oncology Program is changing how outcomes of clinical trials are shared with patients and other non-clinical audiences by publishing summaries of trials led by Dana-Farber Cancer Institute. The documents, called plain language summaries, provide a structured synopsis of each trial’s focus, reason for being conducted, results, and how the trial may help advance research. “Our patients are not only our trial participants – they’re also our partners,” states Erica Mayer, MD, MPH, director of Clinical Research at Dana-Farber and a medical oncologist in Breast Oncology. “It’s important for our patients to learn from the research as much as we, the researchers, do. We hope that the creation of plain language summaries for clinical trials led by Dana-Farber is part of our routine research process. We also hope to serve as a model for other treatment centers here and in the greater medical community.” Read the plain language summaries from Breast Oncology at https://bit.ly/48TjsGV. #breastcancer #breastcancerawareness #cancerresearch

The inaugural paper in the Special Issue on Cardio-Oncology, authored by Professor Jiaxiang Wang from the Cancer Hospital of the University of Chinese Academy of Sciences, and Dr. K. Sharma from iCardioOncology 三度医学, marks the beginning of an insightful exploration into this crucial medical intersection. 👏

Acral, mucosal, pediatric, and uveal melanomas – what we collectively call rare melanomas – represent an area of profound unmet medical need. We know far less about these melanoma subtypes, including what causes them, how they progress, and how to effectively treat them. From investing more than $20 million through over 50 awards specifically focused on rare melanomas, to creating community-driven resources like the Acral and Mucosal Melanoma Model Catalogs, and launching MRA’s RARE Melanoma Registry - MRA is a leader in moving critical research into rare melanomas forward. On Rare Cancer Day, learn more about what MRA is doing to advance rare melanoma research. #RareCancerDay #melanoma #research www.curemelanoma.org

📢 Edward Liu, a member of Geisinger Commonwealth School of Medicine’s class of 2025, presented at the Pennsylvania Society of Oncology and Hematology’s (PSOH) annual conference last fall. The abstract was on the use of radiotherapy in treating patients at the terminal stage of illness with a prognosis of 30 days or less. This collaborative project involved palliative care, radiation oncology, and cancer specialists. The research aimed to better understand the impact of radiation therapy on patients in their last month of life, including patient characteristics, cancer course, type and duration of radiation, involvement of palliative care, and the association with aggressive cancer care metrics. The findings were published in the Journal of Pain and Symptom Management under the title "Radiation Therapy in the Last Month of Life: Association with Aggressive Care at the End of Life" by Davis MP, Vanenkevort E, Young A, et al. #MedicalResearch #PalliativeCare #RadiationTherapy